Sanofi beefing up diabetes pipeline, sees growth returning

PARIS (Reuters) - Sanofi sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday.